One amino acid apart, and a very different amount of evidence. GHK-Cu occurs naturally in human plasma and has five decades of skin and wound-healing research behind it. AHK-Cu is a designed analogue with a much smaller, mostly in-vitro literature concentrated on hair follicle research.
| GHK-Cu from $50 | AHK-Cu from $80 | |
|---|---|---|
| Sequence | Gly-His-Lys + Cu | Ala-His-Lys + Cu |
| Occurs naturally | Yes, in human plasma | No, designed analogue |
| First described | 1973 | Considerably later |
| Research focus | Skin repair, collagen, wound models | Hair follicle and dermal papilla |
| Literature depth | Five decades, including gene-expression work | Small, largely in vitro |
| Strengths stocked | 50MG, 100MG | 50MG, 100MG |
Both are copper-binding tripeptides, and the copper is the functional part: it is a required cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin. The peptide largely acts as the carrier that delivers it.
GHK-Cu was isolated from human plasma in the 1970s, and its concentration is known to decline with age — the observation the entire field grew from. AHK-Cu is synthetic, was never a human plasma peptide, and its research record is correspondingly shorter.
Swapping glycine for alanine at the first position adds a methyl group — slightly larger, slightly more hydrophobic — while leaving the copper-binding histidine and lysine intact. The copper chemistry is essentially shared; what differs is where researchers have looked.
They also differ by 14 daltons, which matters commercially: mass spectrometry separates them instantly and a purity assay alone does not. Two products sold side by side under near-identical names is exactly the situation where identity confirmation earns its place.
GHK-Cu research covers collagen and glycosaminoglycan synthesis in fibroblast culture, wound models, and more recently gene-expression profiling. AHK-Cu research reports dermal papilla cell proliferation and follicle elongation in culture. The honest summary is that GHK-Cu is well characterised and AHK-Cu is a compound of active interest.
Both peptides bind copper(II) through the histidine and lysine residues, and the complex is what does the work. Copper is a required cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin into load-bearing structure, and for superoxide dismutase, one of the cell's antioxidant enzymes. Free copper is toxic and tightly controlled in the body; a carrier that binds it firmly enough to transport and loosely enough to hand over is a genuinely useful thing.
GHK binds copper at physiological pH with an affinity that allows exchange with cellular carriers rather than holding the ion inert. That balance — firm but not final — is the property the whole field rests on, and it explains why the copper-free peptide is a different proposition from the complex.
Under-complexed material is the common quality failure in both products and it is invisible to the eye: the blue colour comes from the complex itself, so a vial can look right and be short of copper.
GHK was isolated from human plasma in 1973, and the observation that drove everything after it was that concentrations are highest in early adulthood and fall substantially with age. That made it a natural candidate for skin and repair research long before peptide cosmetics existed as a category.
The literature since covers collagen and glycosaminoglycan synthesis in fibroblast culture, wound-healing models, and more recently gene-expression profiling — one widely cited paper describes modulation of a large number of human genes toward a repair-associated profile. Antioxidant and anti-inflammatory activity is reported alongside the structural effects.
Most of that work concerns topical or local application rather than systemic administration, which is the limitation worth carrying into any reading of it.
AHK-Cu is a designed analogue, not a human plasma peptide, and its research record is correspondingly narrower. Published work includes in-vitro studies reporting increased proliferation of dermal papilla cells and effects on hair follicle elongation in culture — which is why cosmetic interest has centred on hair rather than skin.
The mechanistic reason for that preference is not well resolved. The copper chemistry is essentially shared with GHK-Cu, so a tidy explanation for why one should favour follicles and the other dermis does not exist in the literature. Treating the difference as established would be reading more into a small in-vitro body of work than it supports.
The two differ by a single methyl group, which is 14 daltons. That is trivial for mass spectrometry to resolve and impossible for a purity assay alone: an HPLC trace can read 99% on the wrong peptide. With two similarly named copper peptides sold side by side at similar prices, identity confirmation is the check that distinguishes a supplier who tests from one who relabels.
Heavy-metal screening also needs care here, and it is a point most suppliers gloss: the copper in the complex belongs there, and the contaminants that must read zero are lead, mercury, arsenic and cadmium. A single "heavy metals" figure that does not separate the two is not telling you anything useful.
We make both in 50MG and 100MG. As with every peptide in the range, the larger vial is better value per milligram, and each strength has its own page carrying its own arithmetic.
Copper peptides are also among the compounds where the pre-mixed format is most often chosen, since the reconstituted solution is distinctive — the characteristic blue is a rough visual confirmation that the complex is intact. Mixed in vial and pen cartridge cost nothing extra (or $5 more per vial while a sale is running).
The great majority of published work on copper peptides concerns application to skin or to cells in culture, not systemic administration. That is a real limitation and it cuts both ways: it means the cosmetic-adjacent claims have more behind them than the systemic ones, and it means extrapolating any of it beyond the local context is unsupported.
GHK-Cu in particular appears in the dermatology and wound-healing literature going back decades, and it is one of the few peptides in this catalogue with a research record that predates the current market by a generation. The gene-expression work is more recent and more speculative; the collagen and glycosaminoglycan synthesis work is the older, steadier part.
Neither compound has meaningful human data for systemic use, and any page that presents in-vitro fibroblast results as though they described a whole organism is overstating what was measured.
Both dissolve readily and both produce the characteristic blue solution. Bacteriostatic water is the usual choice over sterile water because the benzyl alcohol in it inhibits bacterial growth, giving a reconstituted vial a useful window of weeks under refrigeration rather than a day or two.
Copper complexes are light-sensitive, so a reconstituted vial belongs in the dark. A solution that has lost its colour has lost the complex, which is the one visual check that actually tells you something.
We make both in Blacktown, NSW, in 50MG and 100MG vials, at ≥99% HPLC purity with 0 ppm contaminant metals — measured separately from the copper that belongs in the molecule. Both are supplied for in-vitro and laboratory research only, and neither is registered in Australia.
Because that is what was studied. The published work concerns skin application and cell culture, not systemic administration, and extrapolating beyond that is unsupported.
The complex has broken down. It is the one visual check on a copper peptide that genuinely tells you something, which is why reconstituted vials belong in the dark.
By one methyl group — 14 daltons. Trivial for mass spectrometry to resolve, invisible to an HPLC purity figure.
GHK-Cu, by decades. It was isolated from human plasma in 1973; AHK-Cu is a designed analogue with a much smaller in-vitro literature.
The blue colour comes from the complex itself, so a vial short of copper can still look right. Correct copper loading is part of identity, not appearance.
Separately from the copper that belongs there. Lead, mercury, arsenic and cadmium must read zero; a single combined figure tells you nothing useful.
Yes. It was isolated from human plasma in 1973, and concentrations decline substantially with age — the observation the research field grew from.
The published in-vitro work on dermal papilla cells and follicle elongation is on AHK-Cu, though the body of evidence is small and the mechanistic reason for the preference is unresolved.
One amino acid: alanine replaces glycine at the first position. GHK-Cu occurs naturally in human plasma; AHK-Cu is a designed analogue.
GHK-Cu, by a wide margin — five decades of skin and wound-healing literature against a small, mostly in-vitro record for AHK-Cu.
Copper is a required cofactor for enzymes including lysyl oxidase, which crosslinks collagen and elastin. The peptide carries it.
No. They are different molecules with different research records, 14 daltons apart on mass spectrometry.
This comparison summarises published research for educational purposes. It is not medical advice. OzPeptides products are sold for research and laboratory use only, not for human consumption. 18+ only.